Resverlogix Corp. (“Resverlogix”) (TSXV:RVX), is pleased to announce its pre-clinical research agreement with NAEJA Pharmaceutical Inc., a leader in pre-clinical drug development. NAEJA is a well recognized pharmaceutical contract research and development company with extensive expertise in the areas of cardiovascular, cancer, central nervous system and infectious disease.
